Physician profile
Kunal Dalal
NPI 1518341023
$1,995.98
in general payments reported to CMS, 2019-2025
25 companies · $492 in 2025
The $492 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.08 · 2021: $55.26 · 2022: $358 · 2023: $229 · 2024: $779 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,499.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $295.95 | 2022-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $285.76 | 2021-2025 | Trulance, Xifaxan |
| Abbvie INC. | $249.36 | 2019-2025 | |
| Conmed Corporation | $175.00 | 2024 | Conmed Biliary, Conmed Hemostasis |
| Janssen Biotech, INC. | $167.23 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Lilly USA, LLC | $108.35 | 2023-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $107.14 | 2023-2025 | Dupixent |
| Gilead Sciences, INC. | $92.83 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $81.74 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $53.51 | 2024-2025 | Ibsrela |
| Corcept Therapeutics | $45.19 | 2023-2025 | Korlym |
| Celgene Corporation | $43.31 | 2022 | |
| Genzyme Corporation | $42.25 | 2024 | |
| Sanofi-Aventis U.S. LLC | $34.61 | 2025 | |
| Pfizer INC. | $31.50 | 2022-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $23.40 | 2025 | Twiist |
| Janssen Pharmaceuticals, INC | $20.01 | 2023 | Xarelto |
| Daiichi Sankyo INC. | $19.78 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.41 | 2024 | Recorlev |
| Madrigal Pharmaceuticals | $18.04 | 2025 | Rezdiffra |
| Insulet Corporation | $17.72 | 2023 | Omnipod |
| Celltrion USA INC. | $17.39 | 2025 | Vegzelma |
| Aimmune Therapeutics, INC. | $16.92 | 2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $15.59 | 2021 | |
| Amgen INC. | $14.99 | 2024 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kunal Dalal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.